Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D3Q0FU
|
|||
Drug Name |
CSL311
|
|||
Drug Type |
Antibody
|
|||
Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 1 | [1] | |
Company |
CSL Behring
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Interleukin 3 receptor alpha (IL3RA) | Target Info | . | [2] |
Interleukin 5 receptor alpha (IL5RA) | Target Info | . | [2] | |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
PI3K-Akt signaling pathway | ||||
Apoptosis | ||||
Jak-STAT signaling pathway | ||||
Hematopoietic cell lineage | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
IL3 Signaling Pathway | ||||
Pathway Interaction Database | IL3-mediated signaling events | |||
Reactome | GPVI-mediated activation cascade | |||
G beta:gamma signalling through PI3Kgamma | ||||
Interleukin-3, 5 and GM-CSF signaling | ||||
RAF/MAP kinase cascade | ||||
Interleukin receptor SHC signaling | ||||
WikiPathways | IL-3 Signaling Pathway | |||
Interleukin-2 signaling | ||||
Interleukin-3, 5 and GM-CSF signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04082754) A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Subjects With Mild-to-moderate Asthma and in Healthy Volunteers. U.S.National Institutes of Health. | |||
REF 2 | Anti-beta(c) mAb CSL311 inhibits human nasal polyp pathophysiology in a humanized mouse xenograft model. Allergy. 2020 Feb;75(2):475-478. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.